Guardant Health
Market Cap
US$15.5b
Last Updated
2021/04/16 23:11 UTC
Data Sources
Company Financials +
Executive Summary
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. More Details
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Adequate balance sheet with limited growth.
Similar Companies
Share Price & News
How has Guardant Health's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GH is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: GH's weekly volatility (7%) has been stable over the past year.
Market Performance
7 Day Return
0.8%
GH
2.7%
US Healthcare
1.3%
US Market
1 Year Return
116.5%
GH
47.1%
US Healthcare
53.9%
US Market
Return vs Industry: GH exceeded the US Healthcare industry which returned 47.1% over the past year.
Return vs Market: GH exceeded the US Market which returned 53.9% over the past year.
Shareholder returns
| GH | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.8% | 2.7% | 1.3% |
| 30 Day | 8.7% | 4.5% | 3.3% |
| 90 Day | -0.5% | 7.4% | 8.9% |
| 1 Year | 116.5%116.5% | 48.6%47.1% | 56.6%53.9% |
| 3 Year | n/a | 12.6%10.2% | 64.4%53.6% |
| 5 Year | n/a | 19.2%15.2% | 120.4%95.7% |
Long-Term Price Volatility Vs. Market
How volatile is Guardant Health's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Is Guardant Health (NASDAQ:GH) Using Debt In A Risky Way?2 months ago | Simply Wall St
Update: Guardant Health (NASDAQ:GH) Stock Gained 100% In The Last Year3 months ago | Simply Wall St
Here's Why We're Not Too Worried About Guardant Health's (NASDAQ:GH) Cash Burn SituationValuation
Is Guardant Health undervalued compared to its fair value and its price relative to the market?
12.23x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate GH's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate GH's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: GH is unprofitable, so we can't compare its PE Ratio to the US Healthcare industry average.
PE vs Market: GH is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GH is overvalued based on its PB Ratio (12.2x) compared to the US Healthcare industry average (3.6x).
Future Growth
How is Guardant Health forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
3.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GH is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GH is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GH is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: GH's revenue (24.3% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: GH's revenue (24.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GH is forecast to be unprofitable in 3 years.
Past Performance
How has Guardant Health performed over the past 5 years?
-31.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GH is currently unprofitable.
Growing Profit Margin: GH is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: GH is unprofitable, and losses have increased over the past 5 years at a rate of 31% per year.
Accelerating Growth: Unable to compare GH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GH is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (23.6%).
Return on Equity
High ROE: GH has a negative Return on Equity (-18.17%), as it is currently unprofitable.
Financial Health
How is Guardant Health's financial position?
Financial Position Analysis
Short Term Liabilities: GH's short term assets ($1.9B) exceed its short term liabilities ($66.8M).
Long Term Liabilities: GH's short term assets ($1.9B) exceed its long term liabilities ($849.4M).
Debt to Equity History and Analysis
Debt Level: GH's debt to equity ratio (59.5%) is considered high.
Reducing Debt: Insufficient data to determine if GH's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GH has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: GH has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 21.6% each year
Dividend
What is Guardant Health current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GH's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GH's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.3yrs
Average management tenure
CEO
Helmy Eltoukhy (41 yo)
8.25yrs
Tenure
US$914,906
Compensation
Dr. Helmy Eltoukhy, PhD is the Co-founder of Guardant Health Inc. and serves as its Chief Executive Officer and Director. Dr. Eltoukhy is a serial entrepreneur and pioneer in the biotech industry. He joine...
CEO Compensation Analysis
Compensation vs Market: Helmy's total compensation ($USD914.91K) is below average for companies of similar size in the US market ($USD11.14M).
Compensation vs Earnings: Helmy's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: GH's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
Experienced Board: GH's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.4%.
Top Shareholders
Company Information
Guardant Health, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Guardant Health, Inc.
- Ticker: GH
- Exchange: NasdaqGS
- Founded: 2011
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: US$15.454b
- Shares outstanding: 100.43m
- Website: https://guardanthealth.com
Number of Employees
Location
- Guardant Health, Inc.
- 505 Penobscot Drive
- Redwood City
- California
- 94063
- United States
Listings
Biography
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOM...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/04/16 23:11 |
| End of Day Share Price | 2021/04/16 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.